CANCER AND LEUKEMIA GROUP B

UMCC的科学和临床研究不断增长 与CALGB的关系。UMCC教职员工参加CALGB科学 和行政委员会。UMCC教职员工设计、指导和主席 许多小组研究并将大量患者(PTS)输入CALGB 学习。在过去的一年中，我们的应计利润增长了40%以上 过去的4年里。UMCC教职员工是核心委员会的成员，并担任 急性白血病。UMCC赞助MCD CCOP，巴尔的摩退伍军人医疗 中心(BVAMC)、参与的当地医生和文斯·隆巴迪 癌症中心(VLCC)。继续这些活动的资金将使 UMCC在科学和行政方面的参与进一步增加 及其在集团中的附属公司。UMCC第一阶段研究(每年2-4次) 经常演变为小组第二阶段研究。UMCC试点研究(通常 与其他CALGB机构一起执行)构成了概念基础 用于白血病、乳腺癌和肺癌的全组研究。UMCC 是最大的白血病累积机构之一，也是 总体上是最大的应计机构。我们的基础科学实验室 研究急性白血病、细胞、动物和临床药理学，以及 细胞和分子生物学以及基础科学实验室 ，形成了一个重要的相关科学资源 一群人。UMCC及其合作机构(BVAMC、MCD、 参与医生和VLCC)建议进一步提高我们的收益 每年有300个条目进入CALGB研究。参与CALGB研究 将为UMCC及其附属医生提供更多的治疗选择 针对该小组正在研究的疾病的患者。最近的新成员 从UMCC到CALGB的三名外科医生将进一步增加主要 会员机构应计费用。UMCC和VLCC的辅助研究 白血病、小细胞肺癌、乳腺癌和 淋巴瘤将对相关科学具有特别重要的意义。这 Grant将允许UMCC继续其高效的科学和 集团的行政参与，并将继续允许我们 在大巴尔的摩/华盛顿地区建立一个科学基地。 这笔赠款还将允许功勋飞行员继续留任 协议，并将允许UMCC监控和收集数据 使UMCC和CALGB互惠互利。

The UMCC has had continuing growth of its scientific and clinical relationships with CALGB. UMCC faculty participate in CALGB scientific and administrative committees. UMCC faculty design, conduct and chair many group studies and enter large numbers of patients (pts) onto CALGB studies. There has been greater than 40% growth in our accrual over the last 4 years. UMCC faculty sit on the core committees and chair the Acute Leukemia. UMCC sponsors the MCD CCOP, the Baltimore VA Medical Center (BVAMC), participating local physicians and the Vince Lombardi Cancer Center (VLCC). Funding to continue these activities will allow further growth in the scientific and administrative participation of UMCC and its affiliates in the group. UMCC phase I studies (2 - 4 per year) frequently evolve into group phase II studies. UMCC pilot studies (often performed with other CALGB institutions) have formed the conceptual basis for groupwide studies in leukemia, breast cancer and lung cancer. UMCC is one of the largest accruing institutions for leukemia and one of the largest accruing institutions overall. Our basic science laboratories studying acute leukemia, cellular, animal and clinical pharmacology, and cellular and molecular biology as well as the basic science laboratories of the VLCC, form an important correlative science resource for the group. UMCC and its collaborating institutions (BVAMC, MCD, participating physicians, and VLCC) propose to further our accrual beyond 300 entries per year onto CALGB studies. Participation in CALGB studies will allow UMCC and its affiliated physicians greater treatment options for patients with diseases under study by the group. The recent addition of three surgeons from UMCC to CALGB will further increment the main member institutional accrual. Ancillary studies in UMCC and VLCC laboratories in leukemia, small cell lung cancer, breast cancer and lymphoma will be of particular importance for correlative science. This grant will allow UMCC to continue its highly effective scientific and administrative participation in the group and will continue to allow us to develop a scientific base in the greater Baltimore/Washington area. This grant will also allow for the continuation of meritorious pilot protocols and will allow UMCC to monitor and collect data which will produce mutual benefit to the UMCC and CALGB.